排序方式: 共有75条查询结果,搜索用时 250 毫秒
1.
2.
Gulley D Teal E Suvannasankha A Chalasani N Liangpunsakul S 《Digestive diseases and sciences》2008,53(11):3012-3017
Background and Aims It is a commonly held notion that patients with cirrhosis do not suffer from deep vein thrombosis (DVT) or pulmonary embolism
(PE) because they are naturally anticoagulated. However, to date, no studies have been carried out that objectively address
this issue. We conducted a study to examine the relationship between cirrhosis and DVT/PE events. Methods A case–control study of patients seen at a tertiary care hospital was performed. Cases were hospitalized patients with biopsy
and/or imaging plus clinical evidence of cirrhosis. Well-matched patients with no known evidence of cirrhosis served as controls.
The DVT/PE events were identified by the international classification of disease-9 (ICD-9) codes and confirmed with radiographic/nuclear
imaging. The Charlson Index was calculated to determine the comorbidity. The incidence of DVT/PE in cirrhotic patients was
also compared to patients with chronic kidney disease (CKD), congestive heart failure (CHF), and solid organ cancers. Results This study consisted of 963 cirrhotics and 12,405 controls. Both the incidence of DVT/PE (1.8 vs. 0.9%, P = 0.007) and Charlson Index scores (3.2 ± 1.8 vs. 0.9 ± 1.5, P < 0.001) were higher in cirrhotics than in the controls. However, in the multivariate analysis, the presence of cirrhosis
was not associated with DVT/PE [odds ratio (OR) 0.87, P = 0.06]. Partial thromboplastin time (PTT; OR 0.88, P = 0.04) and serum albumin (OR 0.47, P = 0.03) were the independent predictors of DVT/PE. The incidence of DVT/PE in cirrhotics (1.8%) was lower than that in patients
with other medical illnesses: 7.1% in CKD, 7.8% in CHF, and 6.1% in cancers. Conclusion Patients with cirrhosis do not have a lower risk of DVT/PE than non-cirrhotic controls without other significant co-morbidities,
such as CHF, CKD, and solid organ cancers. Partial thromboplastin time and serum albumin were found to be independently predictive
of DVT/PE in cirrhotic patients. 相似文献
3.
Wireless capsule endoscopy detects small bowel ulcers in patients with normal results from state of the art enteroclysis 总被引:21,自引:0,他引:21
Liangpunsakul S Chadalawada V Rex DK Maglinte D Lappas J 《The American journal of gastroenterology》2003,98(6):1295-1298
BACKGROUND: Wireless capsule endoscopy (WCE) is a new technology for small bowel imaging. AIM: To report our initial experience with sensitivity of high quality enteroclysis in patients with small bowel ulcers detected by WCE. METHODS: Medical records of all patients referred for WCE from December, 2001 to April, 2002 at our institution were reviewed. All patients had negative upper and lower endoscopies and small bowel barium studies before WCE. RESULTS: There were 40 patients (19 female, mean age 57.3 yr) during this study period. Three patients had multiple small bowel ulcers detected by WCE. One with ileal ulcers and abdominal pain had an enteroclysis at another hospital before WCE. Review of the study at our institution showed that it was of excellent quality and was normal. Two patients with chronic iron deficiency anemia had multiple small bowel ulcers and were referred after WCE for a repeat small bowel barium study by biphasic enteroclysis performed by experienced GI radiologists. The radiologists were told in advance of the WCE findings. Both studies were considered technically to be of perfect quality. Despite this, both studies were negative. All 3 patients improved after therapy for Crohn's disease. CONCLUSIONS: Our data indicates that WCE may be more sensitive for small bowel ulcers than the best enteroclysis available. 相似文献
4.
Liangpunsakul S Kwo P Koukoulis GK 《European journal of gastroenterology & hepatology》2002,14(3):323-327
In advanced stages of Hodgkin's disease, liver involvement is common. However, Hodgkin's disease mimicking cholestatic hepatitis at presentation is rare. We describe a patient with Hodgkin's disease who was initially considered to have acute cholestatic hepatitis. Liver biopsy demonstrated prominent bile duct injury associated with a florid inflammatory reaction. These changes may represent an early stage of ductal injury, subsequently leading to vanishing bile duct syndrome, a recently documented mechanism of cholestasis in Hodgkin's disease. 相似文献
5.
A number of epidemiologic studies show a protective effect of light to moderate daily alcohol consumption on the development of non-alcoholic fatty liver disease (NAFLD). Although these small amounts of ethanol may prevent fatty liver, they may also be a risk factor for other diseases such as breast and colon cancer. Those individuals who have underlying hepatic steatosis or non-alcoholic steatohepatitis (NASH) should not use ethanol chronically since the data available at present do not support a beneficial effect of alcohol in this situation. Especially overweight and obese individuals may be more susceptible towards alcohol even at moderate doses. Animal experiments show a negative effect of ethanol on liver histology in either dietary or genetic NASH models. In addition, patients with NASH reveal a significant increased risk for hepatocellular cancer (HCC) even with social alcohol consumption. Thus, subjects with underlying NASH should abstain from alcohol at any amounts. 相似文献
6.
INTRODUCTION: There has been an interest to explore whether serum leptin plays any role in the pathogenesis of chronic liver disease. We conducted a case-control study to evaluate the relationship between unexplained elevations in ALT and serum leptin in NHANES III participants. METHODS: A total of 6343 adults who had fasting serum leptin and ALT measured as part of NHANES III constituted our study group. From this database, we have constructed cohorts of patients with unexplained elevations in ALT according to published criteria and compared their serum leptin levels to matched controls without liver disease and matched controls with hepatitis C. Leptin was also compared between patients with unexplained elevations in ALT with and without metabolic syndrome. RESULTS: Serum leptin in 288 patients with unexplained elevations in ALT was 13.3 +/- 9.9 ng/mL and was not significantly different than 720 controls without liver disease (13.6 +/- 11.9 ng/mL, P = 0.6). Serum leptin in another group of patients with unexplained elevations in ALT and hepatitis C controls was also not significantly different (8.0 +/- 4.8 vs. 8.8 +/- 7.4 ng/mL, respectively, P = 0.5). There was no independent relationship between the presence of metabolic syndrome and serum leptin in individuals with unexplained elevations in ALT (P = 0.8). CONCLUSIONS: Individuals with unexplained elevations in ALT did not have higher levels of serum leptin than the matched controls. As unexplained elevations in ALT may signify the presence of nonalcoholic fatty liver disease in NHANES III participants, our data provide indirect evidence against a role for serum leptin in the pathogenesis of nonalcoholic fatty liver disease. 相似文献
7.
Ashish Aggarwal Kanika Puri Suthat Liangpunsakul 《World journal of gastroenterology : WJG》2014,20(19):5737-5745
Patients with liver cirrhosis were traditionally believed to be protected against development of blood clots.Lately,studies have shown that these patients may probably be at an increased risk of venous thrombotic complications.Although the hemostatic changes in the chronic liver disease patients and the factors that may predict bleeding vs thrombotic complications remains an area of active research,it is believed that the coagulation cascade is delicately balanced in these patients because of parallel reduced hepatic synthesis of pro and anticoagulant factors.Thrombotic state in cirrhotic patients is responsible for not only portal or non-portal thrombosis[deep vein thrombosis(DVT)and pulmonary embolism(PE)];it has also been associated with progression of liver fibrosis.The use of anticoagulants in cirrhosis patients is a challenging,and often a scary situation.This review summarizes the current literature on the prevalence of venous thrombosis(DVT and PE),risk factors and safety of prophylactic and therapeutic anticoagulation in patients with chronic liver disease. 相似文献
8.
Arslan Kahloon Naga Chalasani John DeWitt Suthat Liangpunsakul Rakesh Vinayek Raj Vuppalanchi Marwan Ghabril Michael Chiorean 《Digestive diseases and sciences》2014,59(9):2178-2183
Background
Gastric variceal bleeding is associated with significant morbidity and mortality and limited endoscopic therapeutic options.Aim
The aim of this study was to evaluate the short- and long-term efficacy and safety of endoscopic therapy with 2-octyl-cyanoacrylate in patients with gastric variceal bleeding.Methods
A single-center retrospective review of patients receiving endoscopic therapy for gastric variceal hemorrhage. Patient demographics, laboratory, and procedural data were collected. Patients were followed to death, liver transplantation, or last follow-up. Success rates were defined as immediate control of bleeding; early re-bleeding (1–7 days), short-term re-bleeding (1–12 weeks), overall survival, and serious procedure complications.Results
A total of 41 patients (39 with cirrhosis) underwent 54 cyanoacrylate injections during study period. Mean age was 57 and 73 % were males. Twenty-four (58.5 %) patients had failed or were deemed ineligible for transjugular intra-hepatic portosystemic shunt, and 5 % were done for primary prophylaxis. Immediate hemostasis was achieved in five active bleeders. During a median survival time of 117 days, early re-bleeding was seen in 1 (2.4 %), short-term re-bleeding in five patients (12 %), and varices were eradicated in 15 (46.8 %) patients on follow-up. Mean MELD score at the time of the first injection was 17.1 ± 7.8. Mean volume injected was 3.4 cc and median number of varices injected per session was one. Eight patients died during the long-term follow-up: metastatic cancer (2), infections (3), liver failure (1), and re-bleeding (2). There were no serious procedure-related complications.Conclusions
Endoscopic cyanoacrylate therapy appears effective and safe for treatment of patients with bleeding from gastric varices or high-risk stigmata. 相似文献9.
Challenges in Patient Enrollment and Retention in Clinical Studies for Alcoholic Hepatitis: Experience of the TREAT Consortium 下载免费PDF全文
Megan Comerford Spencer Lourens Suthat Liangpunsakul Naga P. Chalasani Arun J. Sanyal Vijay H. Shah Patrick S. Kamath Puneet Puri Barry P. Katz Svetlana Radaeva David W. Crabb 《Alcoholism, clinical and experimental research》2017,41(12):2000-2006
The TREAT Consortium has carried out clinical studies on alcoholic hepatitis (AH) for over 4 years. We encountered problems with participant recruitment, retention, and eligibility for specific protocols. To improve our ability to carry out such trials, we reviewed recruitment screening logs, end of study logs, and surveyed study coordinators to learn the reasons for missing patients, why patients declined enrollment, and the number of patients eligible for treatment trials. Associations of the recruited subjects’ demographics with their adherence to follow‐up appointments were examined. Three hundred eight‐seven patients (AH and heavy drinking controls) were enrolled in the observational study, and 55 AH patients were recruited into treatment trials. About half of patients identified with AH could not be recruited; no specific reason could be determined for about two‐thirds of these. Among the patients who gave a reason for not participating, the most common reasons were feeling too sick to participate, desire to concentrate on abstinence, and lack of interest in research. Approximately a quarter of the AH patients met eligibility criteria for treatment trials for moderate or severe AH and we were able to recruit half to two‐thirds of those eligible. Approximately 35% of participants in the observational study returned for both 6‐ and 12‐month follow‐up visits. We did not identify biopsychosocial or demographic correlates of retention in the study. This analysis revealed that attempts at recruitment into trials for AH miss some subjects because of structural issues surrounding their hospital admission, and encounter a high rate of patient refusal to participate. Nonetheless, more than half of the patients who met the eligibility criteria for moderate or severe AH were entered into clinical trials. Retention rates for the observational study are relatively low. These findings need to be accounted for in clinical trial design and power analysis. 相似文献